+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07086976

Phase 3 Study of Oral Rilzabrutinib Versus Placebo in Adults With Warm Autoimmune Hemolytic Anemia Including Open-label and Long-term Extension Periods

Led by Sanofi · Updated on 2026-10-20

90

Participants Needed

105

Research Sites

82 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults aged 18 and older with warm autoimmune hemolytic anemia wAIHA, a condition where the immune system destroys red blood cells. This Phase 3 trial evaluates the effects, safety, and how the body processes rilzabrutinib compared with a placebo. The goal is to see if rilzabrutinib can increase hemoglobin levels sustainably in participants who have had the disease for at least six months and have not responded well to corticosteroid treatments. Participants will be randomly assigned in a 21 ratio to receive either oral rilzabrutinib or a placebo twice daily during the primary analysis period lasting up to 24 weeks. Those who complete this period can enter an open-label phase lasting 28 weeks where all receive rilzabrutinib. Participants who show improved hemoglobin levels near the end of this phase may continue in a long-term extension that lasts up to 52 weeks from the start of the extension. The study includes a safety follow-up of two weeks after treatment completion or discontinuation. Throughout the study, participants will have multiple visits for assessments including blood tests to measure hemoglobin changes, fatigue levels, and lung function, among others. Researchers will monitor for side effects, vital signs, and laboratory values up to 104 weeks. The primary outcome is the proportion of participants achieving a durable hemoglobin response between weeks 12 and 24. Secondary outcomes include overall hemoglobin response, fatigue improvement, and safety events. The total study duration for participants may extend up to several years depending on eligibility for the long-term extension.

CONDITIONS

Brief Title

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here